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Background. Human immunodeficiency virus (HIV)–asso-
ciated nephropathy (HIVAN) is the most common cause of
end-stage renal disease (ESRD) in HIV-infected patients. An-
giotensin-converting enzyme (ACE) inhibition has previously
shown a short-term benefit in HIVAN. This study examines
the long-term effects of ACE inhibition on renal survival in
HIVAN.
Methods. In this single-center prospective cohort study, 44
patients with biopsy-proven HIVAN were enrolled prior to
the onset of severe renal insufficiency (serum creatinine 2.0
mg/dL), throughout the study period of 1890 days (5.1 years).
Twenty-eight patients received fosinopril, 10 mg/day, and 16
were followed as controls. End points included ESRD and
death. Treatment effects on survival were evaluated with
Kaplan-Meier product-limit estimates. Survival is also de-
scribed as absolute median number of days.
Results. Median renal survival of treated patients was 479.5
days, with only one patient developing ESRD. All untreated
controls progressed to ESRD, with a median renal survival of
146.5 days (P  0.0001). There were no significant differences
between treatment and control groups in age, significant expo-
sure to antiretroviral therapy, defined as two antiviral drugs
for 30 consecutive days, CD4 lymphocyte count, initial me-
dian serum creatinine concentration, or proteinuria. Risk of
renal failure was reduced with ACE inhibitors (RR  0.003,
P  0.0001). Exposure to antiretroviral therapy did not have
a significant impact on the risk of renal failure. Of the ACE
inhibitor–treated group, 87.5% survived compared with 21.4%
of the control group (P  0.001).
Conclusion. ACE inhibition initiated prior to severe re-
nal insufficiency may offer long-term renal survival benefits in
HIVAN. Diagnosis should be sought early in patients with
clinical signs suggestive of HIVAN.
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Human immunodeficiency virus (HIV)–associated ne-
phropathy (HIVAN) is the most common cause of end-
stage renal disease (ESRD) in patients infected with the
HIV-1 [1]. Since 1991, there has been a dramatic rise
in the incidence of HIVAN, and by 1995, in the United
States, this condition was the third leading cause of
ESRD in African Americans between the ages of 20 to 64
years. Despite the impact of highly active antiretroviral
therapy (HAART) on patient survival, there has not been
the expected impact on the incidence of HIVAN [2–4].
HIVAN is typically characterized by normal blood
pressure, nephrotic range proteinuria, and enlarged,
echogenic kidneys. The devastating feature of HIVAN
is its rapid, inexorable progression to ESRD within
weeks to months after the onset of moderate renal insuf-
ficiency or nephrotic range proteinuria [5, 6]. Anecdotal
reports and small case series regarding treatment with
antiviral therapy and steroids have had varied and mostly
nonsustained results [7–10]. No definitive treatment for
HIVAN has been established at this time.
Because of the beneficial effects of angiotensin-con-
verting enzyme (ACE) inhibition in diabetic and other
nondiabetic proteinuric diseases, our group as well as
others have attempted to attenuate the rapidly progres-
sive nature of HIVAN with ACE inhibitors [11–14]. We
previously demonstrated a short-term beneficial effect
of early ACE inhibitor therapy in 20 patients with both
non-nephrotic as well as nephrotic range proteinuria. In
contrast to other studies, therapy was initiated when
serum creatinine concentration was 2.0 mg/dL or below,
and in some patients, with proteinuria of only 500 mg/
day. This led to the speculation that early initiation of
therapy was contributory to renal survival. It was not
known, however, if the renoprotective effects of ACE
inhibition were sustainable. This study extends the previ-
ous short-term study to determine the effect of early
initiation of ACE inhibitors on long-term renal survival
in biopsy-proven HIVAN.
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METHODS
Saint Vincent’s Hospital and Medical Center of New
York is an academic medical institution that treats a large
homosexual male outpatient population with HIV-1 infec-
tion. Between 1993 and 1997, patients seen in the HIV-
related clinics were screened by dipstick for urinary pro-
tein. If positive, measurements of 24-hour urinary protein
excretion and serum creatinine concentrations were ob-
tained. Proteinuria of 500 mg per day was confirmed
on three separate measurements within a 10-day period.
After confirmation of proteinuria, patients were referred
to the HIV renal clinic. During this period, 75 HIV-
positive patients underwent renal biopsy for tissue diag-
nosis of their nephropathy. Of this group of patients, 44
met the following criteria: clinical and pathologic charac-
teristics indicative of HIVAN, serum creatinine concen-
tration2 mg/dL, normal blood pressure, normal serum
potassium, normal blood sugar, no prior renal disease,
no intravenous drug use, and no laboratory evidence of
sickle cell disease.
The constellation of morphologic features used for the
pathologic diagnosis of HIVAN included focal segmen-
tal glomerulosclerosis (FSGS), mostly of the collapsing
variant, microcystically dilated tubules, tubular epithelial
cell atrophy, and tubuloreticular inclusion bodies on elec-
tron microscopic examinations [15]. Presence of moder-
ate or severe interstitial chronic inflammation or fibrosis
was recorded from official pathology reports and used
for statistical analyses. Three specimens had moderate to
severe interstitial fibrosis, and no specimen had fibrosis
without moderate to severe chronic interstitial inflam-
mation. Thus, these two characteristics were combined
under a single designation of “chronic interstitial changes”
for statistical analyses.
Upon entry into the study, all patients underwent a
complete physical examination. Data were collected,
including CD4 cell count, history of opportunistic infec-
tions, and exposure to antiretrovirals and/or cortico-
steroids. Patients prescribed two or more antiretroviral
drugs for 30 consecutive days were considered to have
had a significant exposure to antiretroviral therapy.
Patients were enrolled and followed throughout the
study period of 1890 days (5.1 years). After informed
consent, all patients who met the study criteria were of-
fered treatment with fosinopril (Bristol-Myers Squibb,
Princeton, NJ, USA), 10 mg daily by mouth. Twenty-
eight patients accepted treatment and 16 refused. Pa-
tients who refused therapy were followed prospectively
as naturally selected controls. Reasons for refusing ther-
apy included patient and/or referring physician concerns
of potential hypotensive or hyperkalemic side effects of
fosinopril, and/or an unwillingness to take an experimen-
tal drug. With the exception of the use of fosinopril, all
patients received the same standard of care by the same
nephrologist and remained under the care of their HIV
specialist. Patients were seen every month throughout
the length of the study or until the patient met either
endpoint of dialysis or death. None of the patients were
lost to follow-up. The follow-up period was defined as the
time from study entry to the time of hemodialysis, death,
or study termination. Final serum creatinine and protein-
uria were measured at the end of the follow-up period.
An increase in serum creatinine 30% above the initial
value was considered progressive renal insufficiency. The
Institutional Review Board of Saint Vincent’s Hospital
Manhattan approved all aspects of the study.
Statistical methods
Distributional properties of demographic and clinical
characteristics of patients were evaluated. While age was
approximately normally distributed, all other interval-
scaled clinical variables were skewed. Thus, characteris-
tics of treated and untreated patients for the interval-
scaled variables were compared using the Wilcoxon rank
sum test, except for age, which was compared using the
t test. The likelihood ratio chi-square test was used for
categorical variables. In addition, the effects of other pa-
tient characteristics on the survival experience of pa-
tients were evaluated using Kaplan-Meier product-limit
estimate. For this approach, interval-scaled variables were
dichotomized at the median. Differences in survival were
tested using the log-rank test. Patient characteristics that
were moderately associated with either treatment status
or survival (i.e., P  0.05) were considered as potential
confounders and entered as covariates in later multi-
variate models.
The effect of treatment on survival was described using
Kaplan-Meier product-limit estimates. The log-rank test
was used to compare survival curves. These comparisons
were described using rate ratios with exact 95% CI [16].
Because so few treated patients suffered adverse events
by the study’s termination, there would be too many to
be censored for the calculated means of Kaplan-Meier
product-limit estimates. Therefore, renal and patient sur-
vival days are also described as medians without any
censored data. The calculated median survival times of
those that did not suffer adverse events are understood
to be an underestimated value.
To evaluate whether treatment influenced survival af-
ter adjusting for potential confounders, multivariate mod-
els using Cox proportional hazards regression were de-
veloped [17]. The assumption of proportional hazards
was verified for each covariate in the models by using
graphic and statistical approaches [18]. Statistical signif-
icance of each variable was determined using the Wald
2 model and verified using chi-square comparisons of
model log-likelihood’s with and without the variable [19].
Results are reported as adjusted risk ratios with signifi-
cance level and 95% CI. The above approaches were
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Table 1. Characteristics of patients with non-nephrotic range proteinuria
Antiretroviral Chronic
CD4 therapy Steroid interstitial Interstitial
Patient Age Race Gender cells/mm3 exposure treatment inflammation fibrosis
ACE inhibition
1 40 AA M 80 No No No No
2 25 AA M 450 No No No No
3 37 AA M 1500 No No No No
4 51 H F 340 No No No No
5 40 AA M 170 Yes No Yes No
6 41 AA M 150 No No No No
7 49 AA M 90 Yes No No No
8 30 AA M 100 Yes Yes No No
9 37 AS M 1240 No No Yes No
10 38 AA M 50 No No No No
11 32 AA M 10 Yes No No No
12 35 AA M 40 Yes No No No
13 39 AA M 210 Yes No No No
14 35 AS M 336 Yes No Yes Yes
15 32 AA M 246 Yes No No No
16 46 AA M 216 Yes No No No
Control
17 34 AA M 120 No No No No
18 35 AA M 80 No Yes No No
19 33 AA M 150 Yes No No No
20 22 AA M 120 Yes Yes No No
21 34 AA M 20 No No Yes Yes
22 29 AA M 25 Yes No No No
23 57 AA M 300 Yes No No No
24 32 AA F 10 No No No No
Abbreviations are: ACE, angiotensin-converting enzyme; AA, African American; AS, Asian; H, Hispanic.
applied separately to both outcomes of renal failure and
mortality.
RESULTS
Forty-four patients took part in the study. Tables 1
and 3 summarize the demographics, initial clinical char-
acteristics, and presence of chronic interstitial changes
for patients with non-nephrotic range proteinuria, and
nephrotic range proteinuria, respectively. Tables 2 and
4 present the outcomes for the respective patients. There
were 37 African Americans (84.1%), five Hispanics
(11.4%), and two Asians (4.5%). Of the 44 patients, 41
were male (93.2%) and three were female (6.8%).
Table 5 compares initial and follow-up characteristics
by treatment group. There were no statistically signifi-
cant differences in mean age, median CD4 cell count,
initial median serum creatinine, initial median protein-
uria, or presence of moderate to severe chronic intersti-
tial changes between treatment and control groups. Al-
though not statistically significant, there was a greater
proportion of the treated group with exposure to antiret-
roviral therapy compared to the untreated group (Table
5). The impact of antiretroviral therapy exposure as well
as other variables on outcome were assessed in multivari-
ate analyses and discussed below. Treated patients dem-
onstrated a preservation of renal function with a median
follow-up serum creatinine of 1.55 mg/dL. Untreated
patients had progressive renal dysfunction with a median
serum creatinine of 9.55 mg/dL at follow-up (P 0.0001).
Proteinuria also stabilized in the treated group, while
controls showed significant progression (Table 5).
All 16 untreated patients developed ESRD, while only
one of 28 (3.6%) treated patients progressed to ESRD
(P 0.0001). Four other patients in the treatment group
(patients 4 and 5 of Table 1, and patients 1 and 8 of
Table 3) had progressive renal insufficiency by the end
of the follow-up period. However, none had required
dialytic support for the duration of their follow-up. Three
of these four patients (patients 4 and 5 of Table 1, and
patient 1 of Table 3) had a follow-up time of 1000 days
or more. The absolute median renal survival of untreated
and treated patients was 146.5 and 479.5 days, respec-
tively (P 0.0001). Renal survival is also described using
Kaplan-Meier survival functions (Fig. 1). Treated pa-
tients experienced a significant prolongation of renal sur-
vival compared to controls (P  0.0001).
Of the untreated group, 87.5% died during the study
period, compared with 21.4% of the treated patients
(P  0.001) (Table 5). Figure 2 shows the Kaplan-Meier
curves for overall patient survival. Using the log-rank
test, the difference was statistically significant (P 
0.0001).
Multivariate analyses for several variables on renal
outcome are shown in Table 6. Treatment with ACE
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Table 2. Outcome of patients with non-nephrotic range proteinuria
Initial serum Initial 24-hour Follow-up serum Follow-up 24-hour Follow-up
Patient creatinine mg/dL proteinuria g/24 hours creatinine mg/dL proteinuria g/24 hours days Renal status Outcome
ACE inhibition
1 1.7 1.4 1.1 0.2 1890 Stable Alive
2 1.2 0.6 1.1 0.3 1320 Stable Alive
3 1.1 1.8 1.3 3.0 1290 Stable Alive
4 1.3 2.0 2.3 7.6 1140 RI Alive
5 1.1 2.0 3.1 0.7 1140 RI Alive
6 1.2 2.0 1.5 0.4 1050 Stable Alive
7 1.0 1.1 0.9 0.4 1043 Stable Alive
8 1.2 2.0 1.3 0.2 870 Stable Alive
9 1.6 2.0 1.9 2.5 546 Stable Alive
10 1.4 1.5 1.2 1.2 540 Stable Deceased/sepsis
11 1.0 1.0 0.8 0.2 410 Stable Deceased/sepsis
12 2.0 0.9 2.0 0.2 360 Stable Alive
13 2.0 1.0 1.0 1.0 330 Stable Alive
14 1.9 0.5 1.2 0.2 210 Stable Alive
15 1.1 1.2 0.9 1.0 180 Stable Alive
16 1.8 2.0 0.9 6.1 180 Stable Alive
Control
17 1.2 1.0 11.4 7.4 336 Dialysis Deceased/sepsis
18 0.7 1.8 10.6 11.0 254 Dialysis Deceased/sepsis
19 0.8 1.2 10.2 9.1 210 Dialysis Deceased/sepsis
20 0.8 0.5 9.6 8.4 196 Dialysis Deceased/sepsis
21 1.1 0.5 9.5 6.6 180 Dialysis Deceased/sepsis
22 1.3 1.0 8.8 9.6 173 Dialysis Deceased/sepsis
23 1.8 2.0 8.8 6.4 120 Dialysis Alive
24 2.0 2.0 9.2 4.0 33 Dialysis Deceased/sepsis
Abbreviations are: ACE, angiotensin-converting enzyme; RI, renal insufficiency.
Table 3. Characteristics of patients with nephrotic range proteinuria
Antiretroviral Steroid Chronic interstitial Interstitial
Patient Age Race Gender CD4 therapy exposure treatment inflammation fibrosis
ACE inhibition
1 37 AA M 450 No No Yes No
2 43 AA M 210 No No Yes No
3 44 AA M 250 No No Yes No
4 38 AA M 32 Yes Yes No No
5 33 AA M 450 Yes No Yes No
6 31 AA M 110 No No Yes No
7 38 H M 32 Yes No No No
8 33 AA M 50 No No No No
9 40 AA M 175 Yes No No No
10 40 H M 900 Yes No Yes Yes
11 34 AA M 22 Yes Yes No No
12 35 H M 34 Yes No No No
Control
13 39 H M 170 No No Yes No
14 39 AA M 130 Yes Yes No No
15 36 AA F 50 No No No No
16 42 AA M 150 No No No No
17 29 AA M 120 No No No No
18 39 AA M 130 No No No No
19 36 AA M 50 No No Yes No
20 35 AA M 20 No No No No
Abbreviations are: ACE, angiotensin-converting enzyme; AA, African American; H, Hispanic.
inhibitors afforded a significant reduction in the risk of
renal failure (RR  0.003, 95% CI 0.0002 to 0.047, P 
0.0001), independent from nephrotic range proteinuria,
CD4 cell count, antiretroviral therapy exposure, or pres-
ence of moderate to severe chronic interstitial changes.
As expected, nephrotic range proteinuria was a signifi-
cant independent risk factor for renal failure, increasing
the risk by more than sevenfold (Table 6). CD4 cell
count less than 100 cells/mm3, exposure to antiretroviral
therapy, or presence of moderate to severe chronic inter-
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Table 4. Outcome of patients with nephrotic range proteinuria
Initial Follow-up Follow-up
Initial serum 24-hour proteinuria serum creatinine 24-hour proteinuria Follow-up Renal
Patient creatinine mg/dL g/24 hours mg/dL g/24 hours days status Outcome
ACE inhibition
1 2.0 4.9 3.5 4.2 1410 RI Alive
2 2.0 4.3 2.1 0.6 1230 Stable Alive
3 1.8 3.5 2.0 1.5 1000 Stable Alive
4 2.0 3.6 1.1 0.2 605 Stable Deceased/CMV
5 2.0 3.9 1.8 1.2 419 Stable Alive
6 1.9 7.6 9.4 4.2 300 Dialysis Deceased/sepsis
7 1.2 3.8 0.8 0.7 218 Stable Deceased/lymphoma
8 1.2 6.7 1.7 3.0 210 RI Deceased/sepsis
9 2.0 4.4 1.8 2.3 210 Stable Alive
10 1.6 3.5 2.0 1.2 180 Stable Alive
11 1.7 13.0 1.6 7.4 180 Stable Alive
12 2.0 11.1 1.9 1.4 180 Stable Alive
Control
13 1.4 6.1 8.3 10.2 180 Dialysis Deceased/cancer
14 2.0 15.0 12.2 13.2 177 Dialysis Alive
15 2.0 8.6 11.0 10.4 98 Dialysis Deceased/sepsis
16 2.0 4.2 9.8 8.1 92 Dialysis Deceased/lymphoma
17 2.0 4.6 8.2 15.5 90 Dialysis Deceased/sepsis
18 1.9 5.7 8.8 8.1 88 Dialysis Deceased/CMV
19 1.9 6.3 11.9 10.2 85 Dialysis Deceased/sepsis
20 2.0 6.6 8.4 7.0 60 Dialysis Deceased/sepsis
Abbreviations are: ACE, angiotensin-converting enzyme; CMV, cytomegalovirus; RI, renal insufficiency.
Table 5. Characteristics of patients by treatment group
Characteristic Untreated (N  16) Treated (N  28) P value
Age years mean (SD) 35.7 (7.4) 37.6 (5.7) 0.20
CD4 median 120 172 0.06
Antiretroviral exposure % (number) 31 (5) 57 (16) 0.12
Initial creatinine mg/dL median 1.85 1.65 0.84
Initial proteinuria g/24 hours median 3.1 2.0 0.61
Chronic interstitial changes moderate/severe 18.8 (3) 32.1 (9) 0.49
Final creatinine mg/dL median 9.55 1.55 0.0001
Final proteinuria g/24 hours median 8.8 1.1 0.0001
Renal survival days median 146.5 479.5 0.0001
Renal failure % (number) 100.0 (16) 3.6 (1) 0.0001
Mortality % (number) 87.5 (14) 21.4 (6) 0.001
stitial changes did not have a significant effect on the
risk of renal failure (Table 6).
Table 7 shows the effects of the same variables on mor-
tality. ACE inhibition was associated with a significant
reduction in risk for mortality, while nephrotic range
proteinuria and CD4 cell count 100 cells/mm3 signifi-
cantly increased the risk for mortality. Neither antiret-
roviral therapy exposure nor presence of moderate to
severe chronic interstitial changes had a significant im-
pact on mortality.
Since the impact of nephrotic range proteinuria on out-
come was great, the characteristics of the experimental
groups were analyzed separately according to presence
of nephrotic range proteinuria (Tables 8 and 9). In pa-
tients with non-nephrotic range proteinuria, there were
no statistically significant differences between the experi-
mental groups in terms of mean age, median CD4 cell
count, exposure to antiretroviral therapy, initial median
serum creatinine and proteinuria, or presence of moder-
ate to severe chronic interstitial changes (Table 8). The
final median serum creatinine of the untreated patients
was significantly greater than treated patients with non-
nephrotic range proteinuria (9.55 mg/dL vs. 1.20 mg/dL,
respectively, P  0.0001). While none of the treated pa-
tients progressed to ESRD in this non-nephrotic range
proteinuria group, all untreated controls progressed to
ESRD (P  0.0001). Mortality was also significantly
higher in the untreated patients compared with the treated
patients (Table 8).
In patients with nephrotic range proteinuria, no statis-
tically significant differences were found in initial charac-
teristics between experimental groups (Table 9). There
was a trend toward a greater proportion of patients ex-
posed to antiretroviral therapy in the treatment group
Wei et al: Long-term renal survival in HIVAN with ACE inhibition 1467
Fig. 1. Kaplan-Meier survival estimate of re-
nal failure by treatment group.
Fig. 2. Kaplan-Meier survival estimate of mor-
tality by treatment group.
Table 6. Multivariate analysis for predictors of renal failure
Characteristic Risk ratio 95% confidence interval P value
Nephrotic range proteinuria (yes vs. noa) 7.66 1.91–30.76 0.004
CD4 count (100 vs. 100a) 2.73 0.82–9.14 0.102
Antiretroviral exposure (yes vs. noa) 1.51 0.37–6.20 0.564
Chronic interstitial changes (moderate/severe) 1.04 0.25–4.30 0.958
ACE inhibition treatment (yes vs. noa) 0.003 0.0002–0.047 0.0001
ACE is angiotensin-converting enzyme.
a Reference category
(58% of treated vs. 13% of untreated), but this was not
statistically significant (P  0.07). Patients in the treated
group demonstrated a preservation of renal function
with follow-up median serum creatinine of 1.85 mg/dL
from an initial value of 1.95 mg/dL. Untreated controls
progressed from an initial median serum creatinine of
2.00 mg/dL to 9.30 mg/dL at follow-up (Table 9). The
final median 24-hour proteinuria of treated patients de-
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Table 7. Multivariate analysis for predictors of mortality
Characteristic Risk ratio 95% confidence interval P value
Nephrotic range proteinuria (yes vs. noa) 7.82 2.33–26.28 0.001
CD4 count (100 vs. 100a) 3.92 1.42–10.84 0.008
Antiretroviral exposure (yes vs. noa) 1.00 0.30–3.34 0.999
Chronic interstitial changes (moderate/severe) 0.73 0.19–2.90 0.657
ACE inhibition treatment (yes vs. noa) 0.01 0.002–0.08 0.0001
ACE is angiotensin-converting enzyme.
a Reference category
Table 8. Characteristics of patients with non-nephrotic range proteinuria by treatment group
Characteristic Untreated (N  8) Treated (N  16) P value
Age years mean (SD) 34.5 (10.0) 37.9 (6.8) 0.10
CD4 median 100 190 0.08
Antiretroviral exposure % (number) 50 (4) 56 (9) 0.99
Initial creatinine mg/dL median 1.15 1.25 0.27
Initial proteinuria g/24 hours median 1.1 1.5 0.42
Chronic interstitial changes moderate/severe 12.5 (1) 18.8 (3) 0.99
Final creatinine mg/dL median 9.55 1.20 0.0001
Final proteinuria g/24 hours median 7.9 0.6 0.0003
Renal survival days median 249.5 708.0 0.0027
Renal failure % (number) 100.0 (8) 0.0 (0) 0.0001
Mortality % (number) 87.5 (7) 12.5 (2) 0.0005
Table 9. Characteristics of patients with nephrotic range proteinuria by treatment group
Characteristic Untreated (N  8) Treated (N  12) P value
Age years mean (SD) 36.9 (3.9) 37.2 (4.1) 0.97
CD4 median 125 143 0.49
Antiretroviral exposure % (number) 13 (1) 58 (7) 0.07
Initial creatinine mg/dL median 2.00 1.95 0.40
Initial proteinuria g/24 hours median 6.2 4.4 0.16
Chronic interstitial changes moderate/severe 25.0 (2) 50.0 (6) 0.37
Final creatinine mg/dL median 9.30 1.85 0.0007
Final proteinuria g/24 hours median 10.2 1.5 0.0003
Renal survival days median 138.5 274.0 0.002
Renal failure % (number) 100.0 (8) 8.3 (1) 0.0001
Mortality % (number) 87.5 (7) 33.3 (4) 0.02
creased from 4.4 g to 1.5 g, compared with an increase
of proteinuria from 6.2 g to 10.2 g of the controls. All
untreated patients with nephrotic range proteinuria pro-
gressed to ESRD, while only one of 12 (8.3%) treated
patients developed ESRD (P  0.0001). Of the control
group, 87.5% died during the study period, compared
with 33.3% of the treated patients (P  0.02).
DISCUSSION
Up to 10% of patients with HIV infection, particularly
men of African descent, will develop HIVAN [20, 21]
According to the most recent United States Renal Data
System (USRDS) report [22], an increasing percentage
of those with ESRD are reported with acquired immuno-
deficiency syndrome (AIDS) nephropathy. Patients are
now living longer with HAART, and manifestations of
late-stage disease, such as HIVAN, are increasingly pre-
velant [1, 23].
The pathogenesis of HIVAN is not well understood,
making specific therapeutic concepts difficult to develop.
There are conflicting data regarding the presence and
the role of direct viral infection of renal parenchymal
cells. Expression of the HIV transgene was shown to be
necessary for the HIVAN phenotype in the murine
model of HIVAN by Bruggeman et al [24]. The same
investigators also demonstrated HIV DNA and mRNA
within renal parenchymal cells in human renal tissue
specimens of HIVAN [25]. Other investigators have
shown conflicting findings, however [26]. Furthermore,
the finding of viral DNA or mRNA in renal parenchymal
cells has not been proven to be specific for HIVAN,
suggesting a role for host factors in disease manifestation
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[25, 27]. Given the racial predilection of the disease, one
plausible host factor would be genetic predisposition.
To date, there have been no prospective randomized
trials with any form of therapy for HIVAN. Results from
small case series and anecdotal reports of corticosteroid
therapy show transient improvement in renal function
with a high relapse rate and a discouraging number of
infectious complications [8, 10]. The effects of HAART
on HIVAN are limited to anecdotal reports or studies
with questionable pathologic confirmation of HIVAN
[7, 9, 28, 29].
Prolonged renal survival with ACE inhibitors is well
established in a variety of proteinuric nephropathies,
leading to interest in its use with HIVAN [30–33]. Bird
et al [34] examined the effects of ACE inhibitors in the
murine model for HIVAN and demonstrated decreased
glomerular injury and mortality. In a retrospective study
of 18 patients, Kimmel, Mishkin, and Umana [13] found
prolonged renal survival associated with ACE inhibitor
therapy. In that study, three of the four patients with
the longest renal survival had initiated ACE inhibitor
therapy prior to an elevation of serum creatinine concen-
tration above 2.3 mg/dL. Burns et al [14] demonstrated
the renoprotective effects of early ACE inhibition in
HIVAN in a prospective cohort of 20 patients. ACE
inhibition was initiated prior to the onset of severe renal
insufficiency (serum creatinine2.0 mg/dL) and resulted
in stabilization of renal function compared to untreated
controls.
Our study shows that the renoprotective effects of
early ACE inhibition in HIVAN is sustainable long-
term. Renal survival was significantly prolonged with
ACE inhibition, independent of nephrotic status, antiret-
roviral therapy exposure, low CD4 lymphocyte count,
or presence of moderate to severe chronic interstitial
changes. The presence of moderate to severe chronic
interstitial changes did not have an impact on outcomes;
however, the numbers of pathologic specimens reported
with this poor prognostic variable may be too few to
reach statistical significance in our study.
The therapeutic effects of ACE inhibitors in HIVAN
are likely multifactorial. The link between the renin-
angiotensin system and inflammatory/fibrogenic modu-
lators such as transforming growth factor- (TGF-) and
nuclear factor-B (NF-B), has been well established in
glomerulopathies where fibrosis is an important patho-
logic feature [35, 36]. Compared to other glomerulopa-
thies, higher levels of TGF- were found in kidney tissue
from patients diagnosed with HIVAN [37, 38]. Studies
by Zhang et al [39] suggest that activation of the renin-
angiotensin system is necessary for TGF- expression
and subsequent renal tubular cell hypertrophy in vitro.
Successful attenuation of TGF- expression and renal
tubular cell apoptosis with the blockade of ACE was
demonstrated by Bird et al [34] and Kelly et al [40].
Angiotensin II was shown by Guijarro and Egido [41]
to stimulate another inflammatory modulator, NF-B.
Consequently, angiotensin receptor antagonism prevented
its activation. These studies support an anti-inflammatory
and antifibrogenic effect of ACE inhibitors and other
inhibitors of the renin-angiotensin system.
In addition to a marked effect on renal survival, ACE
inhibition was also associated with a significant risk re-
duction for overall mortality in our study. Interpretation
of results regarding mortality is difficult, however, since
most of the untreated controls died within the first 10
months of their enrollment. Moreover, multivariate anal-
yses of antiretroviral therapy failed to show a statistically
significant impact on mortality. This may be because
most patients were enrolled prior to the era of HAART.
Future studies of ACE inhibitors in HIVAN in the mod-
ern era of HAART would be of interest.
Nephrotic range proteinuria significantly increased the
risk of mortality as a confounding variable, suggesting
that the survival benefit of ACE inhibition relates to its
antiproteinuric effects. Nevertheless, there is an increas-
ing body of evidence that ACE inhibition is associated
with improved overall patient survival in a variety of
conditions, ranging from proteinuric nephropathies to
patients with only marginal proteinuria [42–44]. In recent
years, an indirect effect of ACE inhibition on HIV infec-
tion has been implicated. ACE has been shown to en-
hance HIV antigen presentation to T lymphocytes in vitro
[45]. ACE inhibition may confer a form of protease inhi-
bition that could have some other inhibitory properties
both in nephropathic pathways as well as other systemic
pathways yet to be described [46]. Tat, an HIV-1 regula-
tory gene product, has been shown to increase produc-
tion of TGF-, which, in turn, may increase expression
of HIV promoter genes [47, 48]. NF-B, previously dis-
cussed above, is another transcriptional regulator of HIV
that may be affected by the renin-angiotensin system [49].
Through its attenuation of TGF- and NF-B, ACE
inhibition may indirectly affect viral transcription.
A salient feature of this study was the diagnosis and
initiation of therapy prior to the onset of severe renal in-
sufficiency. In those who received treatment, ACE inhi-
bition was initiated when serum creatinine concentration
was2.0 mg/dL. Many patients were enrolled with serum
creatinine concentrations in the near-normal range. Kim-
mel et al [46] and Burns et al [14] have also speculated
on the significance of early intervention as discussed
above. Case reports of patients with the diagnosis of
HIVAN made shortly after the onset of HIV infection
have been presented by Wali et al [9] and, more recently,
Winston et al [28]. In both cases, HAART was promptly
initiated and renal function improved. In the case report
of Winston et al [28], reduced plasma levels of HIV RNA
and viral activity in renal tissue was demonstrated after
therapy, suggesting that lower levels of viral forms in
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the kidney allowed for recovery of renal function. Our
study adds validity to the concept that early diagnosis
and treatment is a major feature of the management of
HIVAN.
Although subjects were not randomized in this pro-
spective study, confounding variables were statistically
similar between experimental groups. Admittedly, there
is the possibility of noncompliance with general medical
care amongst the untreated controls, thereby affecting
outcome. It is of note, however, that all patients who
declined ACE inhibitor therapy remained compliant
with close follow-up with the same nephrologist through-
out the duration of the study.
In this study, eight of the ACE inhibitor–treated pa-
tients demonstrated renal survival for 1000 days or more,
despite the absence of HAART. Although HAART is
considered part of the standard of care for advanced
HIV disease in developed countries, more than 95% of
new HIV infections occur in economically disadvantaged
regions such as sub-Saharan Africa and the Caribbean
[50]. Access to antiretroviral medications in these regions
is severely limited. ACE inhibition may provide an af-
fordable form of therapy that is easily administered with
a favorable side effect profile that may prolong renal
survival in HIVAN even in the absence of HAART in
developing countries.
Our results show that ACE inhibition initiated prior to
the onset of severe renal insufficiency offers sustainable
renoprotective benefits. The authors therefore advocate
that tissue diagnosis be sought as early as possible in pa-
tients with clinical signs suggestive of HIVAN: protein-
uria in excess of 500 mg/day and normal to enlarged echo-
genic kidneys by ultrasonography in the appropriate clin-
ical context. A screening policy for proteinuria or even
microalbuminuria for those at particular risk of developing
HIVAN may afford the earliest opportunity to initiate
therapy for the maximal benefits of ACE inhibition.
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